COST-EFFECTIVENESS OF ORAL PROTEASE INHIBITORS CO-ADMINISTRATION VERSUS PEGYLATED INTERFERON-Α 2B AND RIBAVIRIN ONLY FOR THE PATIENTS WITH HEPATITIS C GENOTYPE 1 IN KAZAKHSTAN HEALTH CARE SETTINGS

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

ALMADIYEVA ALIMA; IBRAYEV SERIK; TURGAMBAYEVA ASIYA; KOSTYUK ALEXANDR; KHISMETOVA ZAYITUNA; AKHMETOVA ZHANAR

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Public Health Year:2018 | Volume:47 | Issue:12 Page(s): 1845-1853

Download Full-Text

View:

220

Download:

213

Cites:

Information Journal Paper

Title

COST-EFFECTIVENESS OF ORAL PROTEASE INHIBITORS CO-ADMINISTRATION VERSUS PEGYLATED INTERFERON-Α 2B AND RIBAVIRIN ONLY FOR THE PATIENTS WITH HEPATITIS C GENOTYPE 1 IN KAZAKHSTAN HEALTH CARE SETTINGS

Author(s)

Keywords

HEPATITIS C

ANTIVIRAL TREATMENT

PROTEASE INHIBITORS

COST-EFFECTIVENESS

Abstract

Background: The triple therapy including peginterferon, ribavirin and PROTEASE INHIBITORS was more effective compared to the combination of only peginterferon and ribavirin. This study aimed to assess the COST-EFFECTIVENESS of triple treatment in either treatment-naï ve and treatment-experienced patients in Kazakhstan. Methods: A Markov model was created to assess long-term clinical advantages and the COST-EFFECTIVENESS of the triple therapy from Kazakhstan payer perspective. Health state transition probabilities, pharmaceutical and other costs (according to the price in 2015), and utility rate were acquired from the published studies and pub-licly available sources. All used costs and benefits were discounted at 5% per year. Results: Despite treatment background, the patients, receiving boceprevir and telaprevir, were estimated to experience less serious liver-disease complications, more life-years, and more QALYs compared to the patients having standard of care. For treatment-experienced group, boceprevir and telaprevir were dominant, with more QALYs. For all the groups of patients, incremental costs per QALY gained were between USD14995 and USD18075. The total average cost of boceprevir is slightly more costly than a standard duration of treatment with telaprevir, and so is the average cost per SVR. Extensive sensitivity analyses verified robust model results. Conclusion: The inclusion of PROTEASE INHIBITORS to standard management for the therapy of patients with genotype 1 chronic HCV infection in Kazakhstan is predicted to be cost-effective using a typically applied will-ingness to pay threshold of USD37805 (3 times GDP per capita).

Cites

No record.

References

No record.

Cite

APA: Copy

ALMADIYEVA, ALIMA, IBRAYEV, SERIK, TURGAMBAYEVA, ASIYA, KOSTYUK, ALEXANDR, KHISMETOVA, ZAYITUNA, & AKHMETOVA, ZHANAR. (2018). COST-EFFECTIVENESS OF ORAL PROTEASE INHIBITORS CO-ADMINISTRATION VERSUS PEGYLATED INTERFERON-Α 2B AND RIBAVIRIN ONLY FOR THE PATIENTS WITH HEPATITIS C GENOTYPE 1 IN KAZAKHSTAN HEALTH CARE SETTINGS. IRANIAN JOURNAL OF PUBLIC HEALTH, 47(12), 1845-1853. SID. https://sid.ir/paper/274811/en

Vancouver: Copy

ALMADIYEVA ALIMA, IBRAYEV SERIK, TURGAMBAYEVA ASIYA, KOSTYUK ALEXANDR, KHISMETOVA ZAYITUNA, AKHMETOVA ZHANAR. COST-EFFECTIVENESS OF ORAL PROTEASE INHIBITORS CO-ADMINISTRATION VERSUS PEGYLATED INTERFERON-Α 2B AND RIBAVIRIN ONLY FOR THE PATIENTS WITH HEPATITIS C GENOTYPE 1 IN KAZAKHSTAN HEALTH CARE SETTINGS. IRANIAN JOURNAL OF PUBLIC HEALTH[Internet]. 2018;47(12):1845-1853. Available from: https://sid.ir/paper/274811/en

IEEE: Copy

ALIMA ALMADIYEVA, SERIK IBRAYEV, ASIYA TURGAMBAYEVA, ALEXANDR KOSTYUK, ZAYITUNA KHISMETOVA, and ZHANAR AKHMETOVA, “COST-EFFECTIVENESS OF ORAL PROTEASE INHIBITORS CO-ADMINISTRATION VERSUS PEGYLATED INTERFERON-Α 2B AND RIBAVIRIN ONLY FOR THE PATIENTS WITH HEPATITIS C GENOTYPE 1 IN KAZAKHSTAN HEALTH CARE SETTINGS,” IRANIAN JOURNAL OF PUBLIC HEALTH, vol. 47, no. 12, pp. 1845–1853, 2018, [Online]. Available: https://sid.ir/paper/274811/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops